AT156361T - Proteinhaftige drug sustained release - Google Patents

Proteinhaftige drug sustained release

Info

Publication number
AT156361T
AT156361T AT93920157T AT93920157T AT156361T AT 156361 T AT156361 T AT 156361T AT 93920157 T AT93920157 T AT 93920157T AT 93920157 T AT93920157 T AT 93920157T AT 156361 T AT156361 T AT 156361T
Authority
AT
Austria
Prior art keywords
proteinhaftige
sustained release
drug sustained
drug
release
Prior art date
Application number
AT93920157T
Other languages
German (de)
Inventor
Michael J Hageman
Original Assignee
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US94787292A priority Critical
Priority to US96336592A priority
Application filed by Upjohn Co filed Critical Upjohn Co
Publication of AT156361T publication Critical patent/AT156361T/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/25Growth hormone-releasing factor [GH-RF] (Somatoliberin)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/27Growth hormone [GH] (Somatotropin)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
AT93920157T 1992-09-21 1993-08-23 Proteinhaftige drug sustained release AT156361T (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US94787292A true 1992-09-21 1992-09-21
US96336592A true 1992-10-20 1992-10-20

Publications (1)

Publication Number Publication Date
AT156361T true AT156361T (en) 1997-08-15

Family

ID=27130263

Family Applications (1)

Application Number Title Priority Date Filing Date
AT93920157T AT156361T (en) 1992-09-21 1993-08-23 Proteinhaftige drug sustained release

Country Status (12)

Country Link
US (1) US6011011A (en)
EP (1) EP0661989B1 (en)
JP (2) JP3756512B2 (en)
AT (1) AT156361T (en)
AU (1) AU5018693A (en)
DE (2) DE69312947D1 (en)
DK (1) DK0661989T3 (en)
ES (1) ES2107051T3 (en)
GR (1) GR3024632T3 (en)
MX (1) MX9305729A (en)
TW (1) TW224055B (en)
WO (1) WO1994006452A1 (en)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2197258T3 (en) 1996-01-11 2004-01-01 PHARMACIA & UPJOHN COMPANY aqueous depot formulation comprising factor release of bovine growth hormone.
US5932547A (en) * 1996-07-03 1999-08-03 Alza Corporation Non-aqueous polar aprotic peptide formulations
PT909175E (en) * 1996-07-03 2003-10-31 Alza Corp Non-aqueous formulations of protic peptides
US5981489A (en) * 1996-07-18 1999-11-09 Alza Corporation Non-aqueous protic peptide formulations
IN184589B (en) 1996-10-16 2000-09-09 Alza Corp A method for preparing a stable protein composition
US7732404B2 (en) * 1999-12-30 2010-06-08 Dexcel Ltd Pro-nanodispersion for the delivery of cyclosporin
US6358513B1 (en) 2000-02-15 2002-03-19 Allergan Sales, Inc. Method for treating Hashimoto's thyroiditis
US6524580B1 (en) 2000-02-15 2003-02-25 Allergan Sales, Inc. Method for treating thyroid disorders
US6773711B2 (en) * 2000-02-15 2004-08-10 Allergan, Inc. Botulinum toxin therapy for Hashimoto's thyroiditis
US6649161B1 (en) 2000-02-22 2003-11-18 Allergan, Inc. Method for treating hypocalcemia
US20040033241A1 (en) * 2000-06-02 2004-02-19 Allergan, Inc. Controlled release botulinum toxin system
US6306423B1 (en) 2000-06-02 2001-10-23 Allergan Sales, Inc. Neurotoxin implant
US20040170665A1 (en) * 2000-06-02 2004-09-02 Allergan, Inc. Intravitreal botulinum toxin implant
DE60116520T2 (en) * 2000-10-10 2006-08-31 Microchips, Inc., Bedford Microchip-reservoir-devices with wireless transmission of energy and data
AU2003278766A1 (en) * 2002-09-04 2004-03-29 Microchips, Inc. Method and device for the controlled delivery of parathyroid hormone
US7074425B2 (en) * 2002-09-26 2006-07-11 Bonewax, Llc Hemostatic compositions and methods
WO2004035537A2 (en) 2002-10-16 2004-04-29 Euro-Celtique S.A. Antibodies that bind cell-associated ca 125/o772p and methods of use thereof
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
CA2540172A1 (en) * 2003-09-25 2005-03-31 Cangene Corporation Liquid human growth hormone formulation containing polyethylene glycol
CA2544678C (en) 2003-11-05 2013-12-31 Sunesis Pharmaceuticals, Inc. Modulators of cellular adhesion
EP1843783B1 (en) * 2005-01-25 2012-05-30 MicroCHIPS, Inc. Control of drug release by transient modification of local microenvironments
TW200640492A (en) 2005-02-21 2006-12-01 Lg Life Sciences Ltd Sustained release composition of protein drug
WO2006135925A2 (en) * 2005-06-10 2006-12-21 Altus Pharmaceuticals Inc. Methods to reduce oxalate concentration by administration of oxalate oxidase crystals
US7756524B1 (en) 2006-01-31 2010-07-13 Nextel Communications Inc. System and method for partially count-based allocation of vocoder resources
US20070178138A1 (en) * 2006-02-01 2007-08-02 Allergan, Inc. Biodegradable non-opthalmic implants and related methods
EP2998314A1 (en) 2007-06-04 2016-03-23 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
MX2010004281A (en) * 2007-10-19 2010-09-10 Sarcode Corp Compositions and methods for treatment of diabetic retinopathy.
DK2219603T3 (en) 2007-11-02 2014-09-01 Acrux Dds Pty Ltd Transdermal delivery system
US9107815B2 (en) 2008-02-22 2015-08-18 Allergan, Inc. Sustained release poloxamer containing pharmaceutical compositions
CN102065893A (en) * 2008-04-15 2011-05-18 萨可德公司 Delivery of LFA-1 antagonists to the gastrointestinal system
EP3239170B1 (en) 2008-06-04 2019-03-20 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
WO2010009319A2 (en) 2008-07-16 2010-01-21 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
WO2011060352A1 (en) * 2009-11-16 2011-05-19 Ipsen Pharma S.A.S. Pharmaceutical compositions of melanocortin receptor ligands
DE102009056745A1 (en) * 2009-12-04 2011-06-09 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system for the administration of peptides
NZ600361A (en) * 2009-12-21 2014-06-27 Ambrx Inc Modified bovine somatotropin polypeptides and their uses
MX2012006980A (en) * 2009-12-21 2012-07-17 Ambrx Inc Modified porcine somatotropin polypeptides and their uses.
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
UY34913A (en) * 2012-07-17 2013-12-31 Bayer New Zealand Ltd Injectable formations antibiotic and methods of application
US9545446B2 (en) 2013-02-25 2017-01-17 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase and their uses
AU2014235209B2 (en) 2013-03-15 2018-06-14 Synergy Pharmaceuticals Inc. Guanylate cyclase receptor agonists combined with other drugs
US9708367B2 (en) 2013-03-15 2017-07-18 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase and their uses
WO2016020901A1 (en) 2014-08-07 2016-02-11 Acerta Pharma B.V. Methods of treating cancers, immune and autoimmune diseases, and inflammatory diseases based on btk occupancy and btk resynthesis rate
CN108884130A (en) 2016-01-11 2018-11-23 药物协和股份有限公司 For treating the preparation and method of ulcerative colitis

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1185340A (en) * 1967-12-19 1970-03-25 Gen Foods Corp Water Dispersable Hydrophilic Colloid Composition.
US4041155A (en) * 1974-10-29 1977-08-09 American Home Products Corporation Long acting somatostatin composition
US3966962A (en) * 1975-03-27 1976-06-29 The Upjohn Company Triacetin solutions of PGE-type compounds
US4301175A (en) * 1980-12-29 1981-11-17 The Upjohn Company E-Type prostaglandin compositions
ZA8301186B (en) * 1982-03-22 1983-11-30 Upjohn Ltd Gelled pge2/triacetin solutions
EP0140255B1 (en) * 1983-10-14 1991-05-15 Sumitomo Pharmaceuticals Company, Limited Sustained-release injections
JPS646173B2 (en) * 1984-04-23 1989-02-02 Kao Corp
KR890002631B1 (en) * 1984-10-04 1989-07-21 아놀드 하베이 콜 Composition of prolonged release of biologically active somatotropin
US4977140A (en) * 1985-08-23 1990-12-11 Eli Lilly And Company Injectable sustained release formulation
JPH0511092B2 (en) * 1985-11-22 1993-02-12 Sansutaa Kk
US4917685A (en) * 1986-05-16 1990-04-17 International Minerals & Chem. Corp. Delivery device for the administration of stabilized growth promoting hormones
FR2606597B1 (en) * 1986-11-17 1989-01-27 Rhone Poulenc Sante New composition for ruminant feed containing a biologically active substance and its preparation
US4795641A (en) * 1987-08-20 1989-01-03 Eastman Kodak Company Polymer blends having reverse phase morphology for controlled delivery of bioactive agents
US5004728A (en) * 1988-03-11 1991-04-02 The Trustees Of The University Of Pennsylvania Methods of increasing milk yields in ruminants
IT1230576B (en) * 1988-10-20 1991-10-28 Angeli Inst Spa Pharmaceutical compositions for oral selective release in the colon
JPH03506040A (en) * 1989-05-16 1991-12-26
NZ234802A (en) * 1989-08-14 1992-11-25 Merck & Co Inc Long acting injectable formulations comprising an avermectin compound and triacetin. treatment for internal and external parasites of animals
US5179189A (en) * 1990-01-19 1993-01-12 Nova Pharmaceutical Corporation Fatty acid terminated polyanhydrides
DE69129110T2 (en) * 1990-05-10 1998-12-10 Bechgaard Int Res A pharmaceutical preparation containing n-glycofurols and n-ethylene glycols
US5091185A (en) * 1990-06-20 1992-02-25 Monsanto Company Coated veterinary implants
US5206219A (en) * 1991-11-25 1993-04-27 Applied Analytical Industries, Inc. Oral compositions of proteinaceous medicaments

Also Published As

Publication number Publication date
JP3756512B2 (en) 2006-03-15
DK661989T3 (en)
ES2107051T3 (en) 1997-11-16
US6011011A (en) 2000-01-04
EP0661989B1 (en) 1997-08-06
DE69312947T2 (en) 1998-01-08
GR3024632T3 (en) 1997-12-31
EP0661989A1 (en) 1995-07-12
TW224055B (en) 1994-05-21
AU5018693A (en) 1994-04-12
JPH08501305A (en) 1996-02-13
MX9305729A (en) 1994-03-31
JP2004285079A (en) 2004-10-14
DE69312947D1 (en) 1997-09-11
WO1994006452A1 (en) 1994-03-31
DK0661989T3 (en) 1998-03-02

Similar Documents

Publication Publication Date Title
DE59406075D1 (en) Medicines containing tramadol sustained Wirkstofffreitsetzung
DK0661045T3 (en) Hydrogel sustained release
DE69315147D1 (en) Drug delivery device
NO302755B1 (en) Morphinan derivatives
DE59310396D1 (en) Coextruded film
DE69323428T2 (en) Morphine controlled release preparations
DE69432121T2 (en) Bupropion containing stabilized drug
AT166534T (en) Germicides drug combinations
DE69302933T2 (en) Drug delivery system
DE69312916D1 (en) Drug delivery devices
FI951098A (en) pharmaceutical packaging
FI980341A (en) 2-oxy-indole derivatives
DE69519300T2 (en) Stable drug-containing oxaliplatin
DE69615704T2 (en) Bioadhesive solid drug form
DE69329067D1 (en) Pyridmidin derivatives
DE69331906D1 (en) Granulated pharmaceutical composition
NO942900L (en) pharmaceutical compounds
DK0659406T3 (en) Drug formulation with controlled release
DE69231313T2 (en) Risedronate drug-containing sustained-release
FI942723A (en) Kertakäyttöannostelija for drugs
DE69922964D1 (en) Ranolazinhaltige drug sustained release
FI946125A (en) Implantaatiolaitteistot release hermoinhibiittoriyhdisteiden
FI950617A (en) The pharmaceutically active diketopiperazines
AT213153T (en) Storage-stable drug forms
NO971422D0 (en) drugs

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee